With the approval, FDA granted SpringWorks a rare pediatric disease priority review voucher.
FDA Approves SpringWorks Therapeutics Treatment for Adult and Pediatric Patients with NF1-PN
With the approval, FDA granted SpringWorks a rare pediatric disease priority review voucher.
